Tao Wang1, Ziqi Chai1, Lijuan Wang1, Bo Liu1, Junbo Zhao1, Jie Ren1, Bo Yang1, Xiaoyong Wei1, Lihua Jiang1, Fuyun Liu2. 1. Department of Anesthesiology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. 2. Department of Pediatric Orthopaedics, The Third Affiliated Hospital of Zhengzhou University, No. 7, Zhengzhou Kangfufront Street, Zhengzhou, 450052, Henan, China. ffy3567@163.com.
Abstract
OBJECTIVES: Ventilation-induced lung injury (VILI) causes a huge economic and social burden, and its prevention and treatment have gained increasing attention in recent years. IL-9 is an important inflammatory factor, but its potential role in VILI remains unclear. This study intended to explore whether blocking IL-9 could alleviate VILI and explore its underlying mechanism. METHODS: Lung injury was induced by mechanical ventilation (MV) in C57BL/6 mice. Changes in inflammatory factors and NLRP3-related proteins were assessed using quantitative reverse transcription-polymerase chain reaction, western blotting, and enzyme-linked immunosorbent assay. Subsequently, Nlrp3-/- mice were used to further elucidate the underlying mechanism. RESULTS: The percentage of Th9 cells in the peripheral blood, bronchoalveolar lavage fluid (BALF), and lung tissues of MV mice was increased compared to those of control mice. Treatment with anti-IL-9 mAb significantly alleviated the changes in lung histopathology, wet/dry lung proportion, total protein content, and neutrophil content in BALF induced by VILI. Additionally, administering anti-IL-9 mAb significantly downregulated the expression levels of inflammatory factors in BALF and lung tissues of mice with VILI. In addition, administering anti-IL-9 mAb inhibited NLRP3 inflammasome activation, as evidenced by the observed downregulation of NLRP3, ASC, cleaved caspase-1, and GSDMD-N. Additionally, NLRP3-deficient mice had lower lung injury induced by VILI than wild-type mice. Furthermore, the anti-IL-9 mAb only partially inhibited VILI in Nlrp3-/- mice. CONCLUSIONS: In MV mice, the anti-IL-9 mAb alleviated lung injury and reduced the secretion and expression of inflammatory factors partly by inhibiting the NLRP3 inflammasome pathway.
OBJECTIVES: Ventilation-induced lung injury (VILI) causes a huge economic and social burden, and its prevention and treatment have gained increasing attention in recent years. IL-9 is an important inflammatory factor, but its potential role in VILI remains unclear. This study intended to explore whether blocking IL-9 could alleviate VILI and explore its underlying mechanism. METHODS: Lung injury was induced by mechanical ventilation (MV) in C57BL/6 mice. Changes in inflammatory factors and NLRP3-related proteins were assessed using quantitative reverse transcription-polymerase chain reaction, western blotting, and enzyme-linked immunosorbent assay. Subsequently, Nlrp3-/- mice were used to further elucidate the underlying mechanism. RESULTS: The percentage of Th9 cells in the peripheral blood, bronchoalveolar lavage fluid (BALF), and lung tissues of MV mice was increased compared to those of control mice. Treatment with anti-IL-9 mAb significantly alleviated the changes in lung histopathology, wet/dry lung proportion, total protein content, and neutrophil content in BALF induced by VILI. Additionally, administering anti-IL-9 mAb significantly downregulated the expression levels of inflammatory factors in BALF and lung tissues of mice with VILI. In addition, administering anti-IL-9 mAb inhibited NLRP3 inflammasome activation, as evidenced by the observed downregulation of NLRP3, ASC, cleaved caspase-1, and GSDMD-N. Additionally, NLRP3-deficient mice had lower lung injury induced by VILI than wild-type mice. Furthermore, the anti-IL-9 mAb only partially inhibited VILI in Nlrp3-/- mice. CONCLUSIONS: In MV mice, the anti-IL-9 mAb alleviated lung injury and reduced the secretion and expression of inflammatory factors partly by inhibiting the NLRP3 inflammasome pathway.
Authors: Darryl Abrams; Matthieu Schmidt; Tài Pham; Jeremy R Beitler; Eddy Fan; Ewan C Goligher; James J McNamee; Nicolò Patroniti; M Elizabeth Wilcox; Alain Combes; Niall D Ferguson; Danny F McAuley; Antonio Pesenti; Michael Quintel; John Fraser; Carol L Hodgson; Catherine L Hough; Alain Mercat; Thomas Mueller; Vin Pellegrino; V Marco Ranieri; Kathy Rowan; Kiran Shekar; Laurent Brochard; Daniel Brodie Journal: Am J Respir Crit Care Med Date: 2020-03-01 Impact factor: 21.405
Authors: G Guggino; M Lo Pizzo; D Di Liberto; A Rizzo; P Cipriani; P Ruscitti; G Candore; C M Gambino; G Sireci; F Dieli; R Giacomelli; G Triolo; F Ciccia Journal: Clin Exp Immunol Date: 2017-08-23 Impact factor: 4.330
Authors: Shelley Gorman; Sian Geldenhuys; Clare E Weeden; Michele A Grimbaldeston; Prue H Hart Journal: Arch Dermatol Res Date: 2018-02-01 Impact factor: 3.017
Authors: Ognjen Gajic; Saqib I Dara; Jose L Mendez; Adebola O Adesanya; Emir Festic; Sean M Caples; Rimki Rana; Jennifer L St Sauver; James F Lymp; Bekele Afessa; Rolf D Hubmayr Journal: Crit Care Med Date: 2004-09 Impact factor: 7.598